chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I felt ill the night of the vaccine. I had a horrible headache, fever, and body aches. I could not lift my arm as I was in a lot of pain. I was chilled and body aches and fever, just was not feeling good at all. It lasted for about 4-5 days, I started feeling better. I was still feeling cold and had body aches, I took Tylenol and Ibuprofen. Then I started having like tonsillitis, I could not swallow anything, the fever came back and a horrible headache. It was bad, I felt like my head was going to explode. That lasted for about 2 days, I could not eat anything, so I went to Urgent Care, they gave me antibiotics and after a few days I started feeling better. I did have twitching in the arm, it was weird, and it was like at which I had not experienced before. About 3 weeks later I felt better. I still have the twitching in my arm on occasion.
Severe diarrhea; A spontaneous report was received from a nurse on 03NOV2022. It described a 57-years-old male patient who had "severe diarrhea" (PT: Diarrhoea) following administration of Vivotif (Typhoid vaccine live oral Ty21A) (lot number: unknown) for immunisation. It was reported that the patient received the second dose of Vivotif on 02NOV2022. On an unknown date in NOV2022, following the second dose of Vivotif the patient had severe diarrhea. The outcome of the reported event was unknown, at the time of this report.  Action taken with Vivotif with respect to the reported event was unknown.  The concurrent conditions, medical history, and concomitant medications of the patient were not reported.  No additional information was reported.  Company comment: It was reported that a patient took Vivotif for immunisation and he had severe diarrhea (diarrhoea). Further information regarding the event is limited. Considering the case information, the role of Vivotif cannot be ruled out and the causality of diarrhoea is assessed as possible. The case is considered non-serious as per medical assessment.; Sender's Comments: It was reported that a patient took Vivotif for immunisation and he had severe diarrhea (diarrhoea). Further information regarding the event is limited. Considering the case information, the role of Vivotif cannot be ruled out and the causality of diarrhoea is assessed as possible. The case is considered non-serious as per medical assessment.
The day after the vaccine my arm was sore and injection site a little red  Starting on July 1 I noticed a rash with warmth and itching it has now increased in area, hot to touch and extremely itchy .
This subject is a 67 year old male who died at home from Ateriosclerotic Cardiovascular Disease while enrolled in the RSV 11 study with RSV vaccine. The subject received RSV Vaccine or Placebo and Influenza Vaccine on 11/1/02. The subject died from Arteriosclerotic Cardiovascular Disease on 9/13/03, 316 days post immunization. Death Certificate 9/17/03: The cause of death was Arteriosclerotic Cardiovascular Disease. No autopsy was performed. The death was reported by the investigator as unrelated to the study vaccine. A 15-day follow up report received 10/22/2003 adds: Additional info received 10/09/2003. Pt, 67 year old male seen 08/12/2003 in cardio clinic reporting doing well overall, blood sugars were stable, CHF stable with medications. Echocardiography performed on 09/03/2003 revealing marked concentric LVH, marked left atrial enlargement, mild mitral regurgitation, mild tricuspid regurgitation with normal pulmonary pressure. No other info is available as pt died at home and no autopsy performed. Diagnosis: Arteriosclerotic Cardiovascular disease. List of additional info received and available with source file: Death certificate: 9/22/2003. Medication Record: 10/16/2002-08/12/2003. Doctors notes: 08/12/2003. Echocardiography report: 09/03/2003. A 15-day follow up report received 10/23/2003 adds no new info.
48hr of fever to 107 R, urticaria, acrocyanosis, sx @ 48hr;
flu-like symptoms, increase m=home O2 requirements, fever and chills on 12/8/23
Mild pain; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Mild pain) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN (Mild pain). At the time of the report, PAIN (Mild pain) had resolved.            This case was linked to MOD-2021-018251 (Patient Link).
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 62-year-old male patient received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 18Sep2023 at 12:00 as dose 1, single (Batch/Lot number: unknown) at the age of 62 years, in left arm for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Oct2023, outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of vaccination failure, covid-19 as Paxlovid from 27Oct2023 to 02Nov2023.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300357905 Same patient, different drug, different event;
Patient states she has had pain in the arm for 2 months. She has shooting pains down her arm and has a hard time holding her arm up.
Upon receiving subQ injection pt fainted. Blood pressure was very low, taken to hospital within 20 min. Given IV fluids, was able to drive back home on her own within 2 hours from hospital.
pt recv vax 24AUG95 & exp chills, fever, muscle aches for 3 days p/vax;sx resolved;3-4 wk p/vax pt devel pain in rt elbow which progressed to back (like swollen muscle);fatigue, insomnia, burning eyes, twitch in eye, pain eye
fever 101; chills; hot flashes; extreme fatigue; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 03-Feb-2021 and was forwarded to Moderna on 03-Feb-2021.    This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (fever 101), CHILLS (chills), HOT FLUSH (hot flashes) and FATIGUE (extreme fatigue) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028L20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Jan-2021, the patient experienced PYREXIA (fever 101), CHILLS (chills), HOT FLUSH (hot flashes) and FATIGUE (extreme fatigue). At the time of the report, PYREXIA (fever 101), CHILLS (chills), HOT FLUSH (hot flashes) and FATIGUE (extreme fatigue) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Pyrexia: 101 101.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment included Tylenol.  patient taken concomitant medications called prevalent for GERD and a anti-histamine for unknown indication.   Reporter did not allow further contact
After the client received the vaccine she was in the observation area and the client approached the nurse and stated that she felt like she was having trouble swallowing and the nurse directed her towards the paramedic. the paramedics checked her out and gave her some water. She wasn't feeling any better so they gave her 50mg of Benadryl at 10:00AM. Her BP was 135/84 at 10:02am, pulse 68, resp 16 and 02 sat 96.  Another dose of Benadryl 50mg was given at 10:15 and vitals were BP 144/92, pulse 64, o2 98. At 10:30am the client was given the epi pen while an ambulance was called. Her vitals were at 10:30am BP 160/96, pulse 81, resp 16, o2sat 99.  Lung sounds were clear with light wheezing when checked at 10:20 She was taken via ambulance to the local hospital.  At 3:25PM- the health department staff called the client to check on her. She answered the phone and said that she was at home sleeping. That they didn't do anything for her at the hospital, that she got another epi pen in the ambulance and no diagnosis was given.
I26.99 - Acute pulmonary embolism, unspecified pulmonary embolism type, unspecified whether acute cor pulmonale present
some speeches came out unclear; arm sore after 3 hours after the shot; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (arm sore after 3 hours after the shot) and SPEECH DISORDER (some speeches came out unclear) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 046B21A and 031B21A) for COVID-19 vaccination.     Concurrent medical conditions included Drug allergy, Food allergy, Allergy to animal (allergy to cats), Allergy to plants (trees), Grass allergy, Allergy to chemicals (sulfates), Allergy to metals (allergy to portronics), Allergy (seasick patch), Depression, Asthma and Cholesterol. Concomitant products included ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) for Anticoagulant therapy, MONTELUKAST and BUDESONIDE, FORMOTEROL FUMARATE (SYMBICORT) for Asthma, BISOPROLOL for Blood pressure high, ROSUVASTATIN for Cholesterol, ESCITALOPRAM for Depression.   On 31-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 30-Apr-2021, the patient experienced PAIN IN EXTREMITY (arm sore after 3 hours after the shot). On 01-May-2021, the patient experienced SPEECH DISORDER (some speeches came out unclear). On 04-May-2021, SPEECH DISORDER (some speeches came out unclear) had resolved. At the time of the report, PAIN IN EXTREMITY (arm sore after 3 hours after the shot) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information was not reported.   This case was linked to MOD-2021-106502 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 06-Jun-2021: The follow up received on 06-june-2021 contains NNI On 29-Jun-2021: The significant follow-up received on 29-06-2021.It contains Patient's height,weight,race was updated and historical condition like allergy to medications,food cat,trees and other products was added In event tab speech disorder was again reported on 02-04-2021 in which outcome was not resolved and fingers cramp event was added.
Complained of "rush in my head/front of head" at 9:15am on 2/12/2021. At 11am, no longer complaining of "rush" feeling, but now reporting fatigue. At 11:34am same day, reported feeling much better and symptoms improved.
Around 10pm on 4/7 I felt a sudden onset of body aches.  I had similar symptoms after the first vaccine so I knew this was an expected side effect and decided to take two Tylenol 500mg and go to bed.  I had a restless night with pain on the injection site, chills, and severe body aches.  At 8:30am on 4/8, I got out of bed and still feeling sick, thought of taking Tylenol again.  I didn't want to take medication on an empty stomach so I took two sips of milk and coffee and two bites of a cookie, when I started feeling severe nausea.  It was a very strong nauseous sensation.  I started sweating.  I stood up from the table to take the cup to the sink and my vision turned partially black.  I thought I had stood up too quickly, so I sat down again.  I walked back to the table and sat down. I felt I was loosing control of my body.  I stood up again with the intention of going back to bed, and started walking towards my bedroom.  I told my husband that I was seeing all black.  I don't recall what happened next.  My husband says that he was asking me if I was alright but didn't answer.  He walked towards me  and I fainted against the pantry door and he was able to hold me.  I lost consciousness for a few seconds.  Paramedics came and took me to emergency room. I was released 2 hours later.  Had a fever of 100.4C in the afternoon with chills and body aches.
PATIENT IS EXPERIENCING COVID ARM, CELLULITIS. ARM IS HOT, SWOLLEN, AND RED. THE BOARDERS ARE GROWING. SHE WAS ORIGINALLY PRESCRIBED KEFLEX AND THEN SWITCHED TO BACTRIM DS.
Information has been received on 06-NOV-2017 regarding a case in litigation from a lawyer and a female consumer of unknown age. The patient's concurrent conditions, medical history and concomitant medications were not reported. The patient was inoculated with ZOSTAVAX (lot number and expiration unknown), subcutaneous on or about 09-OCT-2012 at a pharmacy, as recommended for routine adult health maintenance and for the prevention of shingles. The vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. On or about 28-APR-2016, the patient was treated by a nurse practitioner at a medical center, for the onset of a severe vesicular rash accompanied by weakened immune symptoms, which was diagnosed as herpes zoster, or shingles. The patient has been prescribed gabapentin (NEURONTIN) and valacyclovir hydrochloride (VALTREX) for management of her painful symptoms. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
No additional AEs; A dose of MMR II was mistakenly given by intramuscular route instead of subcutaneous route; This spontaneous report was received from a pharmacist referring to a patient of unknown age and gender. The patient's concurrent conditions, medical history, and concomitant medications were not reported.  On 23-JUL-2021, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) (lot # T006167 with an expiration date on 19-FEB-2022) at a dose of 0.5 milliliters by intramuscular route for prophylaxis  (strength, and anatomical location were not reported) instead of the subcutaneous route (incorrect route of product administration).         No additional adverse events were reported.
devel high fever (?) went to hosp 18NOV93; had a stroke @ hosp on date of dismissal;
The pt experienced an onset of undifferentiated connective tissue approximately 2 weeks post vax.
member received two bi-valent booster vaccines. first: 10-05-2022 and 12-20-2022
Ist dose was a pfizer covie-19 shot, 2nd shot was given as Moderna
This spontaneous report as received from a pharmacist refers to a 32 year old male patient. No pertinent medical history was reported. On 08-OCT-2014, the patient was vaccinated with an expired dose of PNEUMOVAX23 (lot # H022172 and expiration date was 16-AUG-2014) dose 0.5 ml, intramuscular, in the right arm. On an unknown date approximately in 2014, the patient experienced soreness and hotness at the injection site of an unspecified arm after also being administered FLUVIRIN (Novartis) in his right arm and diphtheria toxoid, form an unspecified physician and was prescribed an unspecified antibiotic. The outcome od event soreness and hotness at the injection site of an unspecified arm was reported as recovering/resolving. Causality for the event soreness and hotness at the injection site of an unspecified arm was not provided by the reporter. This is one of the two reports from the same source. This case was linked to MARRS# 141USA008927. Additional information has been requested.
pt states the day he got the vax he was fatigued, nauseated,  headaches, body aches and pain with high fever.  These symptoms went away and then came back 2 days later and lasted about 2 1/2 weeks.  He went to Urgent Care. He was going to be prescribed antibiotics but he didnt have insurance so was told to take over the counter pain relievers.  He had an unexclusive Covid test.
Swollen and sore lymph node adjacent to and above right collar bone. The condition lasted for approximately 10 days.
This spontaneous case was reported by a consumer and describes the occurrence of MUSCULAR WEAKNESS (weakness of left arm/inability to use left arm), MYALGIA (pain in the joints and surrounding muscles) and ARTHRALGIA (pain in the joints and surrounding muscles) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 11-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Jan-2021, the patient experienced MUSCULAR WEAKNESS (weakness of left arm/inability to use left arm), MYALGIA (pain in the joints and surrounding muscles) and ARTHRALGIA (pain in the joints and surrounding muscles). At the time of the report, MUSCULAR WEAKNESS (weakness of left arm/inability to use left arm), MYALGIA (pain in the joints and surrounding muscles) and ARTHRALGIA (pain in the joints and surrounding muscles) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
COVID-19 INFECTION; METALLIC TASTE; This spontaneous report received from a patient through other manufacturer (Pfizer) concerned a 29 year old male. The patient's height, and weight were not reported. The patient's concurrent conditions included: ADHD (Attention-deficit/hyperactivity disorder) and unspecified allergy. The patient previously received covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin, and batch number were not reported, expiry: unknown) dose was not reported, 1 total administered at left leg on 02-MAR-2021 for prophylactic vaccination. Age at time of vaccination was 28 years. The batch number was not reported and has been requested. Concomitant medications included methylphenidate hydrochloride for drug used for unknown indication. It was unknown whether patient had any adverse events following vaccination with covid-19 vaccine ad26.cov2.s (Dose number in series 1). The patient additionally received non-company suspect vaccine included: Spikevax (elasomeran) (form of admin and route of admin were not reported, batch number: unknown expiry: unknown) dose was not reported, administered at left arm on 22-OCT-2021 for prophylactic vaccination (dose number in series 2). On an unspecified date, patient experienced covid-19 infection (dose number in series 2). On 21-JUN-2022, patient took non-company suspect drug Pfizer-Paxlovid (form of admin and route of admin were not reported, batch number GC4026 expiry: unknown) dose was not reported, administered for treatment of Covid-19.  On 21-JUN-2022 at 22:00, the patient experienced metallic taste 2 hours after first dose of Paxlovid  (dose number in series 2). Date of last administration of Paxlovid was 21-JUN-2022.  The action taken with covid-19 vaccine ad26.cov2.s, and elasomeran was not applicable and with Paxlovid was drug discontinued. The patient had not recovered from metallic taste, and outcome of covid-19 infection was not reported. This report was non-serious.
Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in an 81-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Jan-2021 at 10:01 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 07-Jan-2021 at 10:01 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of patient was reported as 81.63 for dose administered on 07-Jan-2021.  No concomitant medications were reported.  Batch number 025L20A underwent temperature excursion on 07-Jan-2021 with temperature 34 degrees Fahrenheit from  09:00 AM to 10:00 PM. This vial was moved to fridge on 05-Jan-2021 and beyond use date for the vial was reported as 27-Jan-2021. Product moved to clinic on 07-Jan-2021.  Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a temperature monitor at every hour.  No treatment medications were reported.   This case was linked to MOD-2022-566976 (Patient Link).
I had severe fatigue, muscle pain and itching. I went to the doctor to check for COVID and tested negative, the doctor suggested for me not to take the second shot. I went back the second week for a second opinion from Dr., and stated I did not need to get the second shot. I begin to develop symptoms of nausea and dizziness; the doctor referred me to a neurologist. I had multiple test ran and was diagnosis with White Matter disease. I am still under doctor care and still have symptoms of itching.
Patient started feeling achy,  having chills, and running a fever at approx. 12:00 PM on 2/4/2020. Patient also has a hot red raised area on her right arm where vaccine was given.  No treatment was done just ice every couple hours off and on. Patient has taken Tylenol and Ibuprofen as needed to help with fever. Patient keeping an eye on it at this time.
p/vax pt lt thigh was very sore to touch & had a big not & was hard;pt states when touches lt thigh baby cries;told to come to ER to be seen by MD;
Patient complain of throat tightness a few minutes after vaccine. Vital signs stable. Physical exam normal. Symptoms resolved 7 minutes later without intervention.